title: Sugammadex: what do we know and what do we still need to know? A review of the recent (2013 to 2014) literature.
abstract: Since its launch in 2008, sugammadex has been considered one of the most significant developments in anaesthesia-related pharmacology. With almost 500 sugammadex-related publications and over nine million patient exposures worldwide, user experience and scientific data have grown exponentially. However, several important questions are yet to be answered. This article reviews the sugammadex-related literature in 2013 and 2014 to determine which of these questions have been answered more fully over the last 18 months and which questions require more information and research.
authors.affiliation: School of Medicine and Pharmacology, University of Western Australia.
authors.forename: T
authors.initials: T
authors.lastname: Ledowski
mesh_terms: D000762:Anesthesia Recovery Period; D001315:Australia; D004305:Dose-Response Relationship, Drug; D006801:Humans; D003473:Neuromuscular Nondepolarizing Agents / Q000037:antagonists & inhibitors*; D000077122:Sugammadex; D047408:gamma-Cyclodextrins / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex
keywords: residual neuromuscular blockade; sugammadex